Relationship Between Dosage of Clopidogrel and Platelet Aggregation in Chinese With Different Genotype

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01710436

Acronym

RDPAC

Enrollment

880

Registered

2012-10-19

Start date

2012-10-31

Completion date

Unknown

Last updated

2013-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Brief summary

This study is a prospective, observational study to estimate the relationship between dosage of clopidogrel and platelet aggregation in Chinese with different genotype. The investigators suppose both pretreatment dosage of clopidogrel before percutaneous coronary intervention (PCI) and CYP2C19 genotype may effect the platelet aggregation as well as clinical outcome.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* accept PCI in Chinese CHD patients * expected dual antiplatelet therapy (DAPT) at least 6 months

Exclusion criteria

* another planned PCI within 6 months

Design outcomes

Primary

Measure	Time frame
Change from Baseline in platelet aggregation	1 month and 6 months after PCI

Secondary

Measure	Time frame
Major adverse cardiovascular events (MACE); Bleeding events	6 months after PCI

Countries

China

Outcome results